PO.TB10.11 · 肿瘤生物学

CAF分泌的骨膜蛋白通过上调MMP1促进BRAF突变型甲状腺乳头状癌的肿瘤侵袭性

CAF-secreted periostin promotes tumor aggressiveness in BRAF - mutant papillary thyroid carcinoma by upregulating MMP1

海报缩略图:CAF分泌的骨膜蛋白通过上调MMP1促进BRAF突变型甲状腺乳头状癌的肿瘤侵袭性
编号 6048 展板 25 时间 4/21 02:00–05:00 区域 Section 25 主讲 Zhuoran Liu, PhD
分会场 Fibroblasts as Architects of the Tumor Microenvironment
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

ZHUORAN LIU, JINYUE LIU, JIE KUANG, WEIHUA QIU

Rujin Hospital, SHANGHAI, China

摘要 Abstract

中文摘要
携带BRAF V600E突变的甲状腺乳头状癌(PTC)有时表现出更高的侵袭性和更高的转移风险;然而,其潜在机制尚未完全阐明。癌症相关成纤维细胞(CAFs)是肿瘤微环境的关键组成部分。本研究旨在探究CAFs在促进BRAF突变型PTC侵袭性中的作用及分子机制。生物信息学分析提示,基质蛋白骨膜蛋白(POSTN)的高表达与BRAF V600E突变型PTC的不良预后相关。我们证明,BRAF突变通过激活MAPK信号通路,促进PTC细胞分泌IL-1beta,进而刺激CAFs表达POSTN。功能实验进一步揭示,CAF分泌的POSTN通过上调基质金属蛋白酶-1(MMP1)显著增强PTC细胞的迁移和侵袭能力。动物实验进一步证实,BRAF抑制剂(encorafenib)与CAFs中POSTN敲低相结合最有效地抑制了PTC的肺转移并延长了小鼠生存期。本研究揭示了一条新的信号轴——BRAF突变/IL-1beta/CAFs/POSTN/MMP1——它在增强PTC侵袭性中发挥关键作用。因此,靶向BRAF并抑制CAF分泌的POSTN的联合治疗策略代表了一种改善侵袭性BRAF突变型PTC预后的有前景的策略。
查看英文原文 English abstract
Papillary thyroid carcinoma (PTC) harboring the BRAF V600E mutation sometimes demonstrates higher invasiveness and an increased risk of metastasis; however, the underlying mechanisms are not fully elucidated. Cancer-associated fibroblasts (CAFs) are key components of the tumor microenvironment. This study aims to investigate the role and molecular mechanisms of CAFs in promoting invasiveness in BRAF -mutant PTC. Bioinformatic analysis suggested that high expression of the stromal protein periostin ( POSTN ) is associated with poor prognosis in BRAF V600E-mutant PTC. We demonstrated that the BRAF mutation, via activating the MAPK signaling pathway, promotes the secretion of IL-1beta by PTC cells, which stimulates CAFs to express POSTN . Functional assays further revealed that CAF-secreted POSTN significantly enhances the migration and invasion capabilities of PTC cells by upregulating matrix metalloproteinase-1 (MMP1). Animal experiments further confirmed that the combination of a BRAF inhibitor (encorafenib) with knockdown of POSTN in CAFs most effectively suppressed lung metastasis of PTC and prolonged mouse survival.​ This study uncovers a novel signaling axi- BRAF mutation/IL-1beta/CAFs/ POSTN / MMP1 -that plays a critical role in enhancing the aggressiveness of PTC. Thus, a combined therapeutic strategy targeting BRAF and inhibiting CAF-secreted POSTN represents a promising strategy to improve the prognosis of aggressive BRAF -mutant PTC.
利益披露 Disclosure
Z. Liu, None.. J. Liu, None.. J. Kuang, None.. W. Qiu, None.

← 返回 AACR 2026 检索